Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,385 | 1,353 | 1,150 | 3,857 | 1,484 |
| Marketable Securities | 12,502 | 19,266 | 25,911 | 41,052 | 52,634 |
| TOTAL | $14,854 | $21,094 | $27,657 | $45,796 | $55,703 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 22 | 22 | 22 | 22 | 22 |
| TOTAL | $22 | $22 | $22 | $22 | $22 |
| Total Assets | $14,876 | $21,116 | $27,679 | $45,818 | $55,725 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,453 | 1,362 | 1,265 | 4,131 | 2,346 |
| Accrued Expenses | 3,737 | 3,773 | 3,966 | 6,161 | 5,741 |
| TOTAL | $5,190 | $5,135 | $5,231 | $10,291 | $8,087 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 221 | 32 | 8 | 5 | 13 |
| TOTAL | $221 | $32 | $8 | $5 | $13 |
| Total Liabilities | $5,411 | $5,167 | $5,239 | $10,296 | $8,099 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 73,334 | 33,192 | 33,192 | 33,192 | 30,174 |
| Common Shares | 33 | 33 | 33 | 30 | 30 |
| Retained earnings | -678,399 | -668,308 | -658,442 | -640,882 | -622,225 |
| TOTAL | $9,466 | $15,950 | $22,441 | $35,522 | $47,625 |
| Total Liabilities And Equity | $14,876 | $21,116 | $27,679 | $45,818 | $55,725 |